CRISPR THERAPEUTICS AG's ticker is CRSP and the CUSIP is H17182108. A total of 439 filers reported holding CRISPR THERAPEUTICS AG in Q2 2022. The put-call ratio across all filers is 1.02 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $3,198,240 | -42.1% | 56,969 | -53.3% | 0.32% | -45.9% |
| Q1 2023 | $5,522,583 | -48.1% | 122,100 | -53.3% | 0.60% | -44.8% |
| Q4 2022 | $10,638,105 | -60.8% | 261,700 | -36.9% | 1.08% | -62.6% |
| Q3 2022 | $27,105,000 | +40.6% | 414,767 | +30.7% | 2.89% | +20.7% |
| Q2 2022 | $19,280,000 | +49.0% | 317,267 | +53.9% | 2.39% | +143.6% |
| Q1 2022 | $12,937,000 | -8.6% | 206,107 | +10.3% | 0.98% | +3.8% |
| Q4 2021 | $14,156,000 | -10.5% | 186,807 | +32.2% | 0.95% | -1.4% |
| Q3 2021 | $15,816,000 | -76.5% | 141,307 | -66.0% | 0.96% | -73.8% |
| Q2 2021 | $67,292,000 | +86.6% | 415,667 | +40.4% | 3.66% | +127.2% |
| Q1 2021 | $36,065,000 | +62.4% | 295,977 | +104.1% | 1.61% | +2.0% |
| Q4 2020 | $22,202,000 | -0.5% | 145,007 | -45.7% | 1.58% | -1.7% |
| Q3 2020 | $22,317,000 | -23.0% | 266,827 | -32.3% | 1.60% | -43.4% |
| Q2 2020 | $28,980,000 | +35.7% | 394,327 | -21.7% | 2.84% | +33.6% |
| Q1 2020 | $21,350,000 | -21.2% | 503,427 | +13.1% | 2.12% | -8.3% |
| Q4 2019 | $27,098,000 | +15.2% | 444,927 | -22.4% | 2.31% | +18.9% |
| Q3 2019 | $23,516,000 | -16.4% | 573,703 | -4.0% | 1.94% | -29.5% |
| Q2 2019 | $28,133,000 | +35.7% | 597,303 | +2.9% | 2.76% | +52.3% |
| Q1 2019 | $20,727,000 | +40.6% | 580,266 | +12.4% | 1.81% | +4.6% |
| Q4 2018 | $14,744,000 | -1.6% | 516,066 | +52.8% | 1.73% | +22.6% |
| Q3 2018 | $14,978,000 | -33.4% | 337,731 | -11.8% | 1.41% | -29.7% |
| Q2 2018 | $22,495,000 | -12.2% | 382,831 | -31.7% | 2.01% | -18.0% |
| Q1 2018 | $25,608,000 | +22.5% | 560,231 | -37.1% | 2.45% | +40.6% |
| Q4 2017 | $20,912,000 | +50.0% | 890,631 | +14.2% | 1.74% | +86.6% |
| Q3 2017 | $13,937,000 | +9.1% | 779,931 | -2.2% | 0.93% | +5.4% |
| Q2 2017 | $12,772,000 | -28.7% | 797,231 | -3.4% | 0.89% | -22.1% |
| Q1 2017 | $17,919,000 | +7.5% | 824,864 | -1.7% | 1.14% | +3.0% |
| Q4 2016 | $16,676,000 | – | 838,791 | – | 1.10% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Versant Venture Management, LLC | 498,558 | $31,294,000 | 31.24% |
| NEA Management Company, LLC | 1,590,002 | $365,593,000 | 10.56% |
| Ariose Capital Management Ltd | 37,900 | $2,379,000 | 9.30% |
| ARK Investment Management | 9,404,071 | $590,294,000 | 2.46% |
| NIA IMPACT ADVISORS, LLC | 80,082 | $5,027,000 | 2.44% |
| Nikko Asset Management Americas, Inc. | 4,619,747 | $291,044,000 | 2.14% |
| PLUSTICK MANAGEMENT LLC | 50,000 | $3,139,000 | 1.98% |
| Integral Health Asset Management, LLC | 120,000 | $7,532,000 | 1.96% |
| Valiant Capital Management, L.P. | 240,683 | $15,108,000 | 1.73% |
| Deuterium Capital Management, LLC | 18,000 | $1,130,000 | 1.45% |